Onkologie. 2018:12(5):224-230 | DOI: 10.36290/xon.2018.041

Is age the limitation of metastatic treatment prostate cancer?

Jana Katolická
Onkologicko-chirurgické oddělení FN u svaté Anny, Brno

The median age of men with prostate cancer is 67,5 years. We have evidence-based information about elderly with metastaticprostate cancer in clinical trials. The age alone in not a contraindication for ARTA therapy (abiraterone acetate + prednisone,enzalutamide) and chemotherapy (docxetaxel,cabazitaxel). The radium-223 is a therapeutic options for bone metastases. The allpossible interactions of treatment should be monitored.

Keywords: seniors, metastatic prostate cancer, ARTA, chemotherapy, radium-223

Published: October 15, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Katolická J. Is age the limitation of metastatic treatment prostate cancer? Onkologie. 2018;12(5):224-230. doi: 10.36290/xon.2018.041.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Scosyrev E, Messing J, Noyes K, et al. Surveillance Epidemiology and End Results (SEER) program and population-based research in urologic onkology: an overview. Urol Oncol 2012;30: 126-32. Go to original source... Go to PubMed...
    2. Climent MA, Torregrosa MD, Vázquez S, et al. Aged patients with metastatic resistant prostate cancer: Should we treat with chemotherapy
    3. www.uroweb.org/guidelines
    4. Droz JP, Balducci L, Bolla M, et al. Backfround for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Clin Rew Onco/Hem 2010;73: 68-91. Go to original source...
    5. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24: 4448-56. Go to original source... Go to PubMed...
    6. Tsai HK, D'Amico AV, Sadetsky N, et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Inst 2007;99: 1516-24. Go to original source... Go to PubMed...
    7. Hussain M, Tangen CM, Berry DL, et al. Intermitent versus continuosus androgen deprivation in prostate cancer. N Engl J Med 2013;368(14): 1314-25. Go to original source...
    8. Kunath F, Grobe HR, Růcker G, et al. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing agonists or surgical castration monotherapy for advanced prostate cancer. Cochrane Datatbase Syst Rev 2014;6:CD009266. Go to original source...
    9. Shore ND, Chowdhury S, Villers A, et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomized, double-blind, phase 2 study. Lancet Oncol 2016;17: 153. Go to original source...
    10. Siemens RD, Klotz L, Heidenreich A, et al. Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN trial. Journal of Urology 2018;189: 147-154. Go to original source...
    11. Tannock IF, de Wit R, Berrry WR, et al. Docetaxel plus prednison or mitoxantrone plus prednison for advanced prostate cancer. N Engl J Med. 2004;351: 1502-1512. Go to original source...
    12. Cha E, Fong L. Imunoterapie karcinomu prostaty: biologické a léčebné aspekty. JCO;2011:3: 308-315.
    13. De Bono JS, Oudard S, Ozguroglu M, at al. Prednisolon plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progresing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376(9747): 1147-54. Go to original source...
    14. de Bono JS, Logothetis CJ, Molina A, et al. Abirateron and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21): 1995-2005. Go to original source...
    15. Parker C, Nilsson S, Heinrich D, et al. Alpha Emitter Radium-233 and Survival in Metastatic Prostate Cancer. N Engl J Med 2013;369(3): 213-223. Go to original source...
    16. Scher HI, Fizazi K, Saad F, et al: AFFIRM Investigators. Increased survival with enzalutamide in prostate cance rafter chemotherapy. N Engl J Med 2012;367: 1187-97. Go to original source...
    17. Gerritse FL, Meulenbeld HJ, Roodhart JML, et al. Analysis of docetaxel therapy in elderly (70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study. Eur J Cancer 2013, http://dx.doi.org/10.1016/j.ejca.2013.06.008 Go to original source...
    18. Italiano A, Ortholan C, Oudard S, et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer Eur Urol 2009;55: 1368-76. Go to original source... Go to PubMed...
    19. Aventis S. Jevtana prescribing information; December 2011, http://www.provenge.com/pdf/prescribing-information.pdf.
    20. Heidenreich A, Bracarda S, Mason M, et al. Safety of cabazitaxel in senior adults with metastatic castartion-resistant prostate cancer: Results of the European compasiionate-use programme. EJ Cancer 2014;50: 1090-1099. Go to original source... Go to PubMed...
    21. Sternberg CN, De Bono JS, Chi KN, et al. Outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treatedwith the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial.J Clin Oncol 2013,31 (suppl 6; abstr 16). Go to original source...
    22. Miller K, Scher HI, Fizazi K, et al. Effect of enzalutamide on health-related quality of life (HRQoL) in men with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel-based therapy: Results from the AFFIRM study. J Clin Oncol 2013,31 (suppl 6; abstr 17). Go to original source...
    23. Fizazi K, Scher HI, Saad F, et al. Impact of enzalutamide, an androgen receptor signaling inhibitor, on time to first skeletal related event (SRE) and pain in the phase 3 AFFIRM study. Ann Oncol 2012,23 (suppl.9, abstr.8960). Go to original source...
    24. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424-33. Go to original source... Go to PubMed...
    25. Graff JN, Baciarello G, Armstrong AJ, et al. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Ann Oncol 2016;27(2): 286-294. Go to original source...
    26. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overal survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13(10): 983-992. Go to original source... Go to PubMed...
    27. Ryan CJ, Smith MR, de Bono JS, et al. Randomized Phase 3 Trial of Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer and No Prior Chemotherapy. N Engl J Med 2013; 368(2): 138-48. Go to original source... Go to PubMed...
    28. Rathkopf DE, Smith MR, De Bono JS, et al. Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302). J Clin Oncol 31, 2013 (suppl; abstr 5009). Go to original source...
    29. Smith MR, Rathkopf DE, Muldera PFA, et al. Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years) Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer. J Urol 2015; 194(5): 1277-1284. Go to original source...
    30. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369(3): 213-23. Go to original source...
    31. Bellera CA, Rainfray M, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol 2012;23: 2166-72. Go to original source...
    32. www.siog.org./content/siog-guidelines

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.